Systemic lupus erythematosus and hormone replacement therapy

Menopause International

Volumn 13, Issue 2, 2007, Pages 65-70

  Gompel, A ^a   Piette, J C ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CARDIOVASCULAR DISEASE; HORMONE REPLACEMENT THERAPY; MENOPAUSE; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GABAPENTIN; GESTAGEN; GLUCOCORTICOID; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHYTOESTROGEN; PRASTERONE; PREDNISONE; PREGNANE DERIVATIVE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STRONTIUM RANELATE; TESTOSTERONE; TIBOLONE; UNINDEXED DRUG; VITAMIN D; LUPUS ANTICOAGULANT;

ANAMNESIS; ANDROGEN THERAPY; AUTOIMMUNITY; BLOOD CLOTTING; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTRACEPTION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MENOPAUSAL SYNDROME; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONSET AGE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SLEEP DISORDER; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; ANIMAL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; RISK ASSESSMENT; WOMEN'S HEALTH;

ANIMALS; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE; PROGESTINS; RESEARCH DESIGN; RISK ASSESSMENT; THROMBOSIS; WOMEN'S HEALTH;

EID: 34347337270     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507780796433     Document Type: Review

References (54)

1. Gompel A, Pelissier C, Kuttenn F, Mauvais-Jarvis P. Hormones and lupus. Rev Med Interne 1985; 6: 543–52.
2. Lahita RG. The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud 1996; 41: 156–65.
3. Ahmed SA, Penhale WJ, Talal N. Sex hormones, immune responses and autoimmune diseases. Am J Pathol 1985; 121: 531–51.
4. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–8.
5. Sanchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2539–49.
6. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case–control study. Arthritis Rheum 2002; 46: 1830–9.
7. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550–7.
8. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev 1984; 5: 435–55.
9. Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109: 1625–33.
10. Ahmed SA, Verthelyi D. Antibodies to cardiolipin in normal C57BL/6J mice: induction by estrogen but not dihydrotestosterone. J Autoimmun 1993; 6: 265–79.
11. Jansson L, Holmdahl R. Estrogen-mediated immunosuppression in autoimmune diseases. Inflamm Res 1998; 47: 290–301.
12. Evans MJ, MacLaughlin S, Marvin RD, Abdou NI. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. Clin Immunol Immunopathol 1997; 82: 258–62.
13. Cutolo M, Sulli A, Capellino S, et al. Sex hormones' influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004; 13: 635–8.
14. Roubinian JR, Talal N, Greenspan JS, et al. Effect of castration and sex hormone treatment on survival, antinucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978; 147: 1568–83.
15. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of antidouble-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 328–37.
16. Kanda N, Tsuchida T, Tamaki K. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1703–11.
17. Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 1978; 21: 480–4.
18. Munoz JA, Gil A, Lopez-Dupla JM, et al. Sex hormones in chronic systemic lupus erythematosus. Correlation with clinical and biological parameters. Ann Med Interne (Paris) 1994; 145: 459–63.
19. Richaud-Patin Y, Alcocer-Varela J, Llorente L. High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995; 47: 267–72.
20. Houssiau FA, Lefebvre C, Vanden Berghe M, et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393–5.
21. Karpuzoglu E, Ahmed SA. Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide 2006; 15: 177–86.
22. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 1195–8.
23. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981; 53: 174–8.
24. Sanchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430–3.
25. Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998; 25: 1515–19.
26. Arden NK, Lloyd ME, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994; 3: 11–13.
27. Mok CC, Lau CS, Ho CT, et al. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 342–6.
28. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997; 24: 2149–52.
29. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus, a randomized trial. Ann Intern Med 2005; 142: 953–62.
30. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 437–9.
31. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1050–4.
32. Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 761–8.
33. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998; 46: 217–22.
34. Kocis P. Prasterone. Am J Health Syst Pharm 2006; 63: 2201–10.
35. Cummings SR. LIFT study is discontinued. BMJ 2006; 332:667.
36. Basaria S, Dobs AS. Clinical review: controversies regarding transdermal androgen therapy in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 4743–52.
37. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7.
38. Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 2005; 52: 3997–4002.
39. Elkik F, Gompel A, Mercier-Bodard C, et al. Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in post-menopausal women. Am J Obstet Gynecol 1982; 143: 888–92.
40. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536–41.
41. Oger E, Alhenc-Gelas M, Lacut K, et al.; SARAH Investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671–6.
42. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006; 13: 643–50.
43. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–32.
44. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al.; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495–500.
45. Canonico M, Oger E, Conard J, et al.; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259–65.
46. Oger E, Alhenc-Gelas M, Plu-Bureau G, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001; 101: 35–43.
47. Canonico M, Oger E, Plu-Bureau G, et al.; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–5.
48. Davey DA. Hormone replacement therapy: time to move on? J Br Menopause Soc 2006; 12: 75–80.
49. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002; 109: 1056–62.
50. Wakatsuki A, Ikenoue N, Shinohara K, et al. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1948–9.
51. Ho JY, Chen MJ, Sheu WH, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 2006; 21: 2715–20.
52. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and metaanalysis. JAMA 2006; 295: 2057–71.
53. Orcel P. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine 2005; 72: 461–5.
54. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006; (4):CD005326.